Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients.

Breast cancer research and treatment - 1 Sept 2008

Tan David S P, Marchió Caterina, Jones Robin L, Savage Kay, Smith Ian E, Dowsett Mitch, Reis-Filho Jorge S

Abstract excerpt

BACKGROUND: We analysed the clinical features, distribution of basal markers, prevalence of oncogene amplification, and outcome of triple negative (TN) compared to those of non-TN cancers in a series of adjuvant-anthracycline treated breast cancer patients. METHODS: We examined the prognostic impact of the TN and BL phenotype in 245 breast cancer patients uniformly treated with adjuvant anthracycline-based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthracyclines
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Chemotherapy, Adjuvant

Share to Immunohistochemistry

Share to In Situ Hybridization

Share to Kaplan-Meier Estimate

Share to Tissue Array Analysis

Source

Identifiers

PMID: 17922188
DOI: 10.1007/s10549-007-9756-8

Genes

CCND1
EGFR
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients.PMID 17922188Read ↗

Characteristics of triple-negative breast cancer.Semantic proximity Read ↗

Triple-negative breast cancer: current state of the art.Semantic proximity Read ↗

Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic AnalysisSemantic proximity Read ↗

Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.Semantic proximity Read ↗

Triple-negative breast cancer: unique biology and its management.Semantic proximity Read ↗

Triple negative breast cancer: looking for the missing link between biology and treatments.Semantic proximity Read ↗

Targeting basal-like breast cancers.Semantic proximity Read ↗

Triple Negative Breast Cancer Subclassified by Immunohistochemistry: Correlation with Clinical and Pathological Outcomes in Patients Receiving Neoadjuvant ChemotherapySemantic proximity Read ↗

Basal phenotype breast cancer: implications for treatment and prognosis.Semantic proximity Read ↗

Prognostic molecular markers and neoadjuvant therapy response in anthracycline-treated breast cancer patientsSemantic proximity Read ↗

Targeted Therapies for Triple-Negative Breast Cancer.Semantic proximity Read ↗

Clinicopathological Characterization of HER2-Low-Expressing Triple-Negative Breast Cancer: Distinct Features From HER2-Zero Subtype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.